Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A
Conference ID: 2066037
Date of call:
Time of call:
Expected Duration: 60 minutes + questions (analysts and general public)
For registered analysts and pre-certified participants:
Toll Free Number: (833) 665-0715
For other participants (webcast, with ability to submit questions during the session):
Management participants will include:
R&D Day Agenda:
• Strategic Outlook (Dr.
• Therapeutic Pipeline – Clinical Stage (Management)
- STI-1499 (neutralizing antibody)
- STI-5656 (abivertinib)
• Therapeutic Pipeline – IND enabling Stage (Management)
- STI-2020 (affinity matured STI-1499)
- STI-2099 (encoded plasmid DNA expressing STI-2020)
• Therapeutic Discovery (Dr.
- Neutralizing antibody cocktail (COVI-SHIELD™)
- Bispecific Neutralizing antibodies
- STI-2030 (Salicyn-30)
- STI-4398 (COVIDTRAP™: ACE2 receptor decoy protein)
- STI-3333 (T-VIVA-19™: protein-based vaccine)
- I-Cell vaccine delivery platform
• Diagnostics (Management)
- COVI-TRACK™: IgG/IgM Antibody Test
- COVI-TRACE™: HP-LAMP Molecular Detection Test
- COVI-STIX™: Viral Antigen Test
The webcast will be available on the Sorrento Therapeutics’ website for 30 days at www.sorrentotherapeutics.com.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage oncolytic virus ("Seprehvir®", “Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™ and T-VIVA-19™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase 1B trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on
For more information, visit www.sorrentotherapeutics.com
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
Sorrento® and the Sorrento logo are registered trademarks of
G-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™, ACE-MAB™, COVI-TRACK™, COVI-STIX™ and COVI-TRACE™ are trademarks of
ZTlido® is a trademark owned by
All other trademarks are the property of their respective owners.
Source: Sorrento Therapeutics, Inc.